CN115666557A - 用于治疗血管紧张素ii相关疾病的咪唑基噻吩磺酰基氨基甲酸酯 - Google Patents

用于治疗血管紧张素ii相关疾病的咪唑基噻吩磺酰基氨基甲酸酯 Download PDF

Info

Publication number
CN115666557A
CN115666557A CN202180021097.2A CN202180021097A CN115666557A CN 115666557 A CN115666557 A CN 115666557A CN 202180021097 A CN202180021097 A CN 202180021097A CN 115666557 A CN115666557 A CN 115666557A
Authority
CN
China
Prior art keywords
compound
disease
methyl
compounds
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180021097.2A
Other languages
English (en)
Chinese (zh)
Inventor
T·菲克斯
B·奥尔森
J·劳德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vicore Pharma AB
Original Assignee
Vicore Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicore Pharma AB filed Critical Vicore Pharma AB
Publication of CN115666557A publication Critical patent/CN115666557A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180021097.2A 2020-03-20 2021-03-18 用于治疗血管紧张素ii相关疾病的咪唑基噻吩磺酰基氨基甲酸酯 Pending CN115666557A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2004094.5A GB202004094D0 (en) 2020-03-20 2020-03-20 New compounds and uses
GB2004094.5 2020-03-20
PCT/GB2021/050674 WO2021186180A1 (en) 2020-03-20 2021-03-18 Imidazolyl thiopehene sulfonyl carbamates for use in the treatment of diseases associated with angiotensin ii

Publications (1)

Publication Number Publication Date
CN115666557A true CN115666557A (zh) 2023-01-31

Family

ID=70546543

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180021097.2A Pending CN115666557A (zh) 2020-03-20 2021-03-18 用于治疗血管紧张素ii相关疾病的咪唑基噻吩磺酰基氨基甲酸酯

Country Status (7)

Country Link
US (1) US20230114153A1 (enExample)
EP (1) EP4121047B1 (enExample)
JP (1) JP7773988B2 (enExample)
CN (1) CN115666557A (enExample)
CA (1) CA3174437A1 (enExample)
GB (1) GB202004094D0 (enExample)
WO (1) WO2021186180A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025044926A1 (zh) * 2023-08-25 2025-03-06 武汉人福创新药物研发中心有限公司 作为at2r激动剂的噻吩磺酰基氨基甲酸酯

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024511453A (ja) * 2021-03-23 2024-03-13 ヴィコール ファルマ アーベー 選択的アンジオテンシンｉｉ受容体リガンド
WO2024133942A1 (en) 2022-12-22 2024-06-27 Vicore Pharma Ab A method of treating a patient diagnosed with an interstitial lung disease
CN120569378A (zh) * 2023-01-09 2025-08-29 维科尔药物公司 选择性血管紧张素ii化合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1349530A (zh) * 1999-05-05 2002-05-15 阿文蒂斯药物德国有限公司 作为血管紧张肽(1－7)受体兴奋剂的1－(p－噻吩基苄基)咪唑,其制备方法,其用途和含有它们的药物制剂
CN1529697A (zh) * 2001-05-31 2004-09-15 ά�ƶ�ҩ�﹫˾ 用作血管紧张素ⅱ激动剂的三环化合物
US20180078529A1 (en) * 2015-03-02 2018-03-22 Vicore Pharma Ab Angiotensin ii receptor agonist for treating pulmonary fibrosis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2096883A (en) * 1933-07-19 1937-10-26 Electrolux Corp Vacuum cleaner
US5312820A (en) 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
WO1994027597A1 (en) * 1993-05-21 1994-12-08 Smithkline Beecham Corporation Imidazolyl-alkenoic acid angiotensin ii receptor antagonists
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
SE9800550D0 (sv) 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
AU2003302106A1 (en) 2002-11-21 2004-06-15 Vicore Pharma Ab New tricyclic angiotensin ii agonists
US8835471B2 (en) 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
US9864250B2 (en) * 2014-11-14 2018-01-09 Heliotrope Technologies, Inc. Post-temperable nanocrystal electrochromic devices
US20170266164A1 (en) 2014-12-12 2017-09-21 Vicore Pharma Ab New methods and uses
WO2016107879A2 (en) 2014-12-30 2016-07-07 Vicore Pharma Ab New use of angiotensin ii receptor agonists
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
GB201710906D0 (en) 2017-07-06 2017-08-23 Vicore Pharma Ab Compounds and methods for treating peripheral neuropathy
GB201913603D0 (en) * 2019-09-20 2019-11-06 Vicore Pharma Ab New compounds
US11123329B1 (en) * 2020-03-23 2021-09-21 Vicore Pharma Ab Use of angiotensin II type 2 receptor agonist
GB202006074D0 (en) * 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006079D0 (en) * 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202201723D0 (en) * 2022-02-10 2022-03-30 Vicore Pharma Ab New use
KR20240148359A (ko) * 2022-02-10 2024-10-11 바이코어 파마 아베 특발성 폐섬유증 치료를 위한 불록시부티드의 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1349530A (zh) * 1999-05-05 2002-05-15 阿文蒂斯药物德国有限公司 作为血管紧张肽(1－7)受体兴奋剂的1－(p－噻吩基苄基)咪唑,其制备方法,其用途和含有它们的药物制剂
CN1529697A (zh) * 2001-05-31 2004-09-15 ά�ƶ�ҩ�﹫˾ 用作血管紧张素ⅱ激动剂的三环化合物
US20180078529A1 (en) * 2015-03-02 2018-03-22 Vicore Pharma Ab Angiotensin ii receptor agonist for treating pulmonary fibrosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WAN, Y.，等: ""Design, Synthesis, and Biological Evaluation of the First Selective Nonpeptide AT2 Receptor Agonist"", 《JOURNAL OF MEDICINAL CHEMISTRY》, vol. 47, no. 24, 18 November 2004 (2004-11-18), pages 5998, XP055080127, DOI: 10.1021/jm049715t *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025044926A1 (zh) * 2023-08-25 2025-03-06 武汉人福创新药物研发中心有限公司 作为at2r激动剂的噻吩磺酰基氨基甲酸酯

Also Published As

Publication number Publication date
WO2021186180A1 (en) 2021-09-23
US20230114153A1 (en) 2023-04-13
CA3174437A1 (en) 2021-09-23
EP4121047B1 (en) 2024-10-30
GB202004094D0 (en) 2020-05-06
JP7773988B2 (ja) 2025-11-20
JP2023518474A (ja) 2023-05-01
EP4121047C0 (en) 2024-10-30
EP4121047A1 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
JP7773988B2 (ja) アンジオテンシンｉｉに関連する疾患の治療における使用のためのイミダゾリルチオフェンスルホニルカルバメート
CN115605265B (zh) 用于治疗和/或预防与血管紧张素ii相关的疾病、病症或病状的新型化合物
CN114786774A (zh) 新化合物
US12441718B2 (en) Selective angiotensin II compounds
WO2022049372A1 (en) Novel compounds for use in the treatment of diseases associated with angiotensin ii
GB2605148A (en) New compounds
JP2024511452A (ja) 選択的アンジオテンシンｉｉ受容体リガンド
JP2026502510A (ja) 選択的アンジオテンシンｉｉ化合物
JP2024511451A (ja) 選択的アンジオテンシンｉｉ受容体リガンド
US20240182461A1 (en) Selective angiotensin ii receptor ligands
HK40081690A (en) Imidazolyl thiophene sulfonyl carbamates for use in the treatment of diseases associated with angiotensin ii
HK40081690B (en) Imidazolyl thiophene sulfonyl carbamates for use in the treatment of diseases associated with angiotensin ii

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination